Ata uhi

Is non-alcoholic steatohepatitis caused by alcohol?

<p>Obesity and the associated diseases such as the metabolic syndrome, hypertryglyceridemia and diabetes mellitus type 2 are the most frequent causes of Non-Alcoholic Fatty Liver Diseases (NAFLD) [1-5]. Over time NAFLD may show mixed lobular inflammatory infiltrates and a ballooning degenerati...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Kaituhi matua:	Hubert E Blum (Author)
Hōputu:	Pukapuka
I whakaputaina:	Archives of Community Medicine and Public Health - Peertechz Publications, 2020-05-26.
Ngā marau:	Commentary
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Fructose and Non-Alcoholic Steatohepatitis
mā: Elke Roeb, me ētahi atu.
I whakaputaina: (2021)

Structure of anaemic conditions comorbid to alcoholic and non-alcoholic steatohepatitis
mā: Oksana Khukhlina, me ētahi atu.
I whakaputaina: (2021)

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients
mā: Singh Deepak, me ētahi atu.
I whakaputaina: (2010)

Non-Alcoholic Steatohepatitis: Clinical and Translational Research
mā: Manuela G Neuman, me ētahi atu.
I whakaputaina: (2016)

Src kinase as a potential therapeutic target in non‐alcoholic and alcoholic steatohepatitis
mā: Dhadhang Wahyu Kurniawan, me ētahi atu.
I whakaputaina: (2022)

Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
mā: Yuko Tsukahara, me ētahi atu.
I whakaputaina: (2022)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
mā: Zhen Yang, me ētahi atu.
I whakaputaina: (2023)

Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
mā: Tharani Senavirathna, me ētahi atu.
I whakaputaina: (2024)

Influence of antidysbiotic drugs on the liver of rats with experimental non-alcoholic steatohepatitis
mā: A. P. Levitsky, me ētahi atu.
I whakaputaina: (2017)

Influence of antidysbiotic drugs on the liver of rats with experimental non-alcoholic steatohepatitis
mā: A. P. Levitsky, me ētahi atu.
I whakaputaina: (2017)

Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
mā: Rosa Lombardi, me ētahi atu.
I whakaputaina: (2021)

β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model
mā: Zigmond E, me ētahi atu.
I whakaputaina: (2014)

Association of Breastfeeding with Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in mothers: A cross sectional survey
mā: Muhammad Zafar Majeed Babar, me ētahi atu.
I whakaputaina: (2024)

Association of Breastfeeding with Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in mothers: A cross sectional survey
mā: Muhammad Zafar Majeed Babar, me ētahi atu.
I whakaputaina: (2024)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
mā: Maxime Nachit, me ētahi atu.
I whakaputaina: (2021)

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
mā: Shinji Takai, me ētahi atu.
I whakaputaina: (2018)

NON-ALCOHOLIC STEATOHEPATITIS IN CHILDREN − A PRACTICAL APPROACH WITH CASE REPORT
mā: Ana Šinkovec, me ētahi atu.
I whakaputaina: (2021)

The Non-Alcoholic Steatohepatitis and Cardiovascular Disease Intersection, an Important Consideration in Drug Development
mā: Seth Baum, me ētahi atu.
I whakaputaina: (2020)

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
mā: Cheng Peng, me ētahi atu.
I whakaputaina: (2020)

A scoring system for the diagnosis of non-alcoholic steatohepatitis from liver biopsy
mā: Kyoungbun Lee, me ētahi atu.
I whakaputaina: (2020)

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
mā: Marina Kawaguchi-Suzuki, me ētahi atu.
I whakaputaina: (2018)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
mā: Jia Xu, me ētahi atu.
I whakaputaina: (2022)

Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report
mā: Ahmed Hashem
I whakaputaina: (2023)

Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting
mā: Dana Balitzer, me ētahi atu.
I whakaputaina: (2022)

The Correlation between Serum Zinc Level and Liver Histology in Non-Alcoholic Steatohepatitis
mā: Farid Kosari, me ētahi atu.
I whakaputaina: (2019)

Features of iron homeostasis in patients with steatohepatitis of alcoholic and non-alcoholic etiology and its correlation with the intensity of oxidative stress and apoptosis
mā: O. S. Khukhlina, me ētahi atu.
I whakaputaina: (2021)

Interrelation between fibrosis, angiogenesis and ductular reaction in progression of chronic steatohepatitis (alcoholic and non-alcoholic) and hepatitis C virus infection
mā: O. M. Gavrilyuk
I whakaputaina: (2014)

Ductular reaction in alcoholic steatohepatitis, nonalcoholic steatohepatitis and hepatitis C virus infection (immunohistochemical study)
mā: O. M. Gavrilyuk
I whakaputaina: (2014)

Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARα and suppressing HIF1
mā: Chaoyuan Huang, me ētahi atu.
I whakaputaina: (2024)

Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis
mā: Baolong Liu, me ētahi atu.
I whakaputaina: (2024)

Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
mā: Xinxue Wang, me ētahi atu.
I whakaputaina: (2023)

Overexpression of ORMDL3 confers sexual dimorphism in diet-induced non-alcoholic steatohepatitis
mā: Ryan D.R. Brown, me ētahi atu.
I whakaputaina: (2024)

Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by MCD diet in rat
mā: Qingping Lan, me ētahi atu.
I whakaputaina: (2021)

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
mā: Torre E, me ētahi atu.
I whakaputaina: (2022)

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
mā: Jingyi Wu, me ētahi atu.
I whakaputaina: (2023)

Effect of Empagliflozin On Liver Enzymes of Patients In Non-Alcoholic Steatohepatitis In Type 2 Diabetes Mellitus
mā: Nauman Wazir, me ētahi atu.
I whakaputaina: (2023)

Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment
mā: Daniel Aggio, me ētahi atu.
I whakaputaina: (2024)

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
mā: Lili Yu, me ētahi atu.
I whakaputaina: (2022)

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report
mā: Yeong Yeh Lee, me ētahi atu.
I whakaputaina: (2023)

Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients
mā: Solène Marie, me ētahi atu.
I whakaputaina: (2023)